SOURCE: TomoTherapy

TomoTherapy

June 22, 2010 16:00 ET

TomoTherapy Signs Radiation Therapy Equipment Agreement With Amerinet

MADISON, WI--(Marketwire - June 22, 2010) -  TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it has signed a purchasing agreement with Amerinet, a leading national healthcare group purchasing organization (GPO). This agreement will make TomoTherapy's premier radiation therapy solutions available to Amerinet's members and will result in a more streamlined purchasing process for Amerinet member facilities seeking an innovative and proven technology for advanced cancer care. 

Amerinet has more than 41,000 members nationwide. 

"Our new agreement with TomoTherapy will benefit our members by expanding their options for radiation oncology systems," said Ken Rosemann, vice president, laboratory and diagnostic imaging for Amerinet.

"Over the years, TomoTherapy system users have published many studies that demonstrate the system's effectiveness for treating a wide array of cancers throughout the body, from the most common to the most complex," said Fred Robertson, TomoTherapy CEO. "We look forward to the opportunity to work with Amerinet member organizations as they seek to improve and enhance cancer treatment alternatives for their patients."

About Amerinet
As a leading national healthcare group purchasing organization, Amerinet strategically partners with acute and alternate care providers to reduce costs and improve quality through its performance solutions. Built on a foundation of data, savings and trust, and supported by a team of clinical and supply chain experts, Amerinet enriches healthcare delivery for its members and communities they serve. To learn more about the Amerinet difference, visit www.amerinet-gpo.com.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Contact Information

  • Investor Contact:
    Thomas E. Powell
    Chief Financial Officer
    608.824.2800
    Email Contact

    Media Contacts:
    Kevin O'Malley
    Manager, Corporate Communications
    608.824.3384
    Email Contact

    Susan Lehman
    Rockpoint Public Relations
    510.832.6006
    Email Contact